tyrosine has been researched along with carbidopa, levodopa drug combination in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (36.36) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cedarbaum, JM; Kutt, H; McDowell, FH | 2 |
| August, TF; Bush, DF; Lasseter, KC; Musson, DG; Schwartz, S; Smith, ME; Titus, DC; Yeh, KC | 1 |
| Berchou, RC; Galloway, MP; Kareti, D; Kesaree, N; LeWitt, PA; Nelson, MV; Schlick, P | 1 |
| Bennett, JP; Schuh, LA | 1 |
| Baraldo, M; Benetello, P; Furlanut, M; Hassan, E; Zara, G | 1 |
| Bankiewicz, KS; Bringas, J; Budinger, TF; Cunningham, J; Eberling, JL; Harvey-White, J; Jagust, W; Kohutnicka, M; Pivirotto, P | 1 |
| aan het Rot, M; Baker, GB; Benkelfat, C; Booij, L; Leyton, M; Young, SN | 1 |
| Adamiak, U; Bialecka, M; Gawronska-Szklarz, B; Kaldonska, M; Klodowska-Duda, G; Safranow, K; Wyska, E | 1 |
| Muhlack, S; Müller, T; Woitalla, D | 1 |
| Chatamra, K; Dutta, S; Johansson, A; Locke, C; Nyholm, D; Odin, P; Othman, AA | 1 |
6 trial(s) available for tyrosine and carbidopa, levodopa drug combination
| Article | Year |
|---|---|
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
Topics: Adolescent; Adult; Aged; Antiparkinson Agents; Biological Availability; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Fasting; Half-Life; Humans; Intestinal Absorption; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Reference Values; Tablets; Tyrosine | 1989 |
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.
Topics: Aged; Antiparkinson Agents; Carbidopa; Clinical Trials as Topic; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Humans; Levodopa; Middle Aged; Parkinson Disease; Random Allocation; Tyrosine | 1989 |
Clinical significance of the relationship between O-methyldopa levels and levodopa intake.
Topics: Animals; Carbidopa; Corpus Striatum; Delayed-Action Preparations; Drug Combinations; Female; Humans; Levodopa; Parkinson Disease; Rats; Rats, Inbred Strains; Tyrosine | 1988 |
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion.
Topics: Adult; Affect; Attention; Carbidopa; Central Nervous System Stimulants; Dextroamphetamine; Dopamine; Double-Blind Method; Drug Combinations; Humans; Levodopa; Male; Motivation; Neuropsychological Tests; Pain Measurement; Phenylalanine; Reaction Time; Tyrosine | 2007 |
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Drug Combinations; Drug Therapy, Combination; Dyskinesias; Enzyme Inhibitors; Female; Half-Life; Humans; Levodopa; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nitrophenols; Parkinson Disease; Severity of Illness Index; Tolcapone; Tyrosine | 2010 |
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Biological Availability; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Drug Combinations; Drug Therapy, Combination; Female; Half-Life; Homocysteine; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Tyrosine | 2011 |
5 other study(ies) available for tyrosine and carbidopa, levodopa drug combination
| Article | Year |
|---|---|
A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine | 1989 |
Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dihydroxyphenylalanine; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Infusions, Intravenous; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Tyrosine | 1993 |
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Antiparkinson Agents; Blood-Brain Barrier; Carbidopa; Delayed-Action Preparations; Dopamine; Dose-Response Relationship, Drug; Drug Combinations; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Tyrosine | 1993 |
Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Carbidopa; Catheterization; Caudate Nucleus; Cell Line; Dependovirus; Dopamine; Drug Administration Routes; Drug Combinations; Fluorine Radioisotopes; Genetic Therapy; Genetic Vectors; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Neurons; Parkinson Disease, Secondary; Prodrugs; Putamen; Tomography, Emission-Computed; Tyrosine; Tyrosine 3-Monooxygenase | 2000 |
Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Biotransformation; Carbidopa; Chemistry, Pharmaceutical; Drug Combinations; Female; Gels; Germany; Humans; Infusion Pumps; Intestinal Absorption; Intubation, Gastrointestinal; Jejunum; Levodopa; Male; Middle Aged; Parkinson Disease; Sweden; Tyrosine | 2013 |